The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)

Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.

Valeant Pharmaceuticals (NYSE: VRX) is slated to release its quarterly performance before the opening bell on Tuesday, August 8. According to estimates from Wall Street, the company is expected to report in the neighborhood of $2.2 billion in sales, which could represent a high single-digit percentage drop in year-over-year sales, along with a profit per share of $0.94. This compares with the $1.40 per share profit the company delivered in Q2 2016. Though past performance is no guarantee of future results, the company has come up short of Wall Street's consensus earnings per share (EPS) figure in five of the past six quarters.

Image source: Getty Images.

Source: Fool.com